

No.25 CENTRAL PHARMACEUTICAL JSC

Add: 448B Nguyen Tat Thanh Street, Ward Xom
Chieu, Ho Chi Minh City, Vietnam

Number: *261* - BC/DPTW25

Explaining fluctuations in income statement

SOCIALIST REPUBLIC OF VIETNAM

Independence - Freedom - Happiness

Ho Chi Minh City, *16th* October 2026

Digitally signed by CÔNG TY
CỔ PHẦN
DƯỢC
PHẨM TW 25
DN: cn=CÔNG TY CỔ PHẦN DƯỢC
PHẨM TW 25, o=CÔNG TY CỔ PHẦN
DƯỢC PHẨM TW 25, ou=CÔNG TY
CỔ PHẦN DƯỢC PHẨM TW 25, email=
DPTW25@CENTRALPHARMACEUTICAL.VN,
c=VN
Reason: I am the author of this
document
Date: 2026.10.17 09:51:44+0700
File: PDF Reader Version: 2026.1.1

**Att: - State Securities Commission of Vietnam;
- Hanoi Stock Exchange**

No.25 Central Pharmaceutical Joint Stock Company (Stock code: UPH) explains changes in business results in 2nd Quarter 2026 compared to 2nd Quarter 2025 as follows:

Items	2nd Quarter 2026	2nd Quarter 2025	In/Decrease	Percentage %
Net revenue	17,475,242,703	26,922,070,566	(9,446,827,863)	-35,09%
Net profit after tax	19,457,573	508,653,905	(489,196,332)	-96,17%

Explain:

The company's profit after tax for the third quarter of 2026 saw a sharp decline compared to the same period in the previous year, a drop of 96.17%, equivalent to a decrease of 489 million VND. This significant reduction was primarily driven by a steep fall in sales revenue, which decreased by 35.09% or 9.45 billion VND; relative to the same period last year. This led to a decline in gross profit, while selling and administrative expenses did not decrease proportionately. Furthermore, in the third quarter of 2025, the company did not record any corporate income tax, as it was able to offset current earnings against accumulated losses from previous years.

We commit that the information published above is true and are fully responsible before the law for the information published.

Best Regards,



GENERAL DIRECTOR

Nguyen Manh Hai